Vigilant Biosciences

Executive Summary

Vigilant Biosciences is a diagnostics company developing the BeVigilant OraFusion System, a point-of-care test for early detection of oral cancer. Oral cancer is often diagnosed at late stages, leading to poor outcomes. The company's device aims to enable clinicians to identify the disease at its most treatable stages, potentially improving survival rates. Founded in 2012 and based in Fort Lauderdale, Florida, Vigilant is focused on commercializing this technology to address a significant unmet need in cancer diagnostics. The market for oral cancer screening is large and underserved, with conventional methods often lacking sensitivity or requiring specialized equipment. Vigilant's platform offers a rapid, non-invasive solution. While the company is private and lacks publicly disclosed funding or revenue data, its long operating history suggests progress in development. Key upcoming catalysts include regulatory clearance, strategic partnerships, and clinical evidence generation. These milestones are critical for market adoption and could drive value creation.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for OraFusion System75% success
• Q2 2027Strategic Partnership with Dental or Oncology Networks60% success
• Q1 2027Publication of Clinical Validation Study Results80% success